## Practitioner's Docket No. MPI96-031CP1DV1CPACN2M

## **REMARKS**

This preliminary amendment is being submitted to accompany a new continuation application filed herewith. Amendments to the specification include an amendment to the paragraph describing related applications to identify the present application as a continuation application of U.S. Application No. 10/052,005. Further amendments to the specification were submitted in a response filed on November 21, 2003 in that prior application. Amendments to the claims cancel the original claims 1-6 and replace them with new claims 7-26. New claims 7-26 are pending upon entry of the instant amendment. Support for new claims 7-26 can be found in the original claims and throughout the specification, for example at pages 67-77. No new matter has been added.

Also submitted herewith is an Information Disclosure Statement referring to Forms 1449, Forms PTO-892 and Forms PTO/SB/08A and 08B listing references previously made of record in prior applications.

In addition, a paper copy of an updated Sequence Listing previously submitted, on November 21, 2003, in U.S. Application No. 10/052,005 is submitted herewith to replace the original sequence listing found at pages 114-117 of the specification. Also included herewith is a copy of the Declaration under 37 CFR § 1.132 submitted on November 21, 2003 together with that updated Sequence Listing to state that additional SEQ ID NO:9 introduces no new matter.

Entry of the preliminary amendments and remarks made herein is respectfully requested.

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

26 March 2004

Takey M. Sioussat

Registration No. 50,609

40 Landsdowne Street Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820